In this study, doctors are testing a new drug called **ipatasertib** along with the usual chemotherapy treatment for advanced ovarian cancer. Ovarian cancer is when cells in the ovaries grow abnormally. **Ipatasertib** is a medicine that may help stop cancer cells from growing. The chemotherapy drugs, **paclitaxel** and **carboplatin**, are already used to treat ovarian cancer by killing cancer cells or slowing their growth. This study aims to find the safest amount of **ipatasertib** to use with these chemotherapy drugs and to see if this combination works better than chemotherapy alone.
**Key Points:**
- The study involves taking **ipatasertib** daily and receiving chemotherapy every 21 days for up to 3 cycles.
- Participants must be followed up after treatment for 30 and 90 days.
- Eligibility includes having advanced ovarian cancer, but no prior ovarian cancer treatments. Certain health conditions may exclude participation.
This research will help determine if the new combination treatment is effective and safe for patients with advanced ovarian cancer. Participants in this study will be closely monitored to ensure their health and safety.
How understandable was the trial content above?
Hard to understand
Easy to understand